RALTEGRAVIR VIATRIS 600mg film-coated tablets medication leaflet

J05AJ01 raltegravir • Antiinfectives for systemic use | Direct acting antivirals | Integrase inhibitors

Raltegravir is a medication used for the treatment of human immunodeficiency virus (HIV) infection. It is an integrase inhibitor that prevents the integration of viral DNA into the host cell genome, thereby reducing viral replication.

The medication is taken orally, usually in tablet form, and should be used in combination with other antiretroviral drugs as directed by your doctor. It is important to adhere to the treatment regimen to prevent the development of viral resistance.

Side effects may include nausea, fatigue, headache, or insomnia. In rare cases, severe adverse effects such as allergic reactions or liver function impairment may occur, requiring immediate medical attention.

Patients should inform their doctor about any other medications being used or pre-existing conditions, such as liver diseases, to ensure the safe use of raltegravir.

General data about RALTEGRAVIR VIATRIS 600mg

Substance: raltegravir

Date of last drug list: 01-10-2025

Commercial code: W71328001

Concentration: 600mg

Pharmaceutical form: film-coated tablets

Quantity: 60

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: MYLAN HUNGARY KFT - UNGARIA

Holder: VIATRIS LIMITED - IRLANDA

Number: 16195/2025/01

Shelf life: 18 months

Pharmaceutical forms available for raltegravir

Concentrations available for raltegravir

100mg, 400mg, 600mg

Other substances similar to raltegravir